Novartis Validates Xenon and its Obesity Programme with US$157 M Deal
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 53 (Table of Contents)
Published: 4 Nov-2004
DOI: 10.3833/pdr.v2004.i53.755 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Novartis Pharma and Xenon entered into research & development agreement for Xenon’s preclinical stearoyl-CoA desaturase-1 (SCD-1) drug development program for treating obesity and other metabolic diseases including metabolic syndrome...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS